Helsinki, Finland 16 May – the Finnish biotech company Mobidiag today announced that its Prove-it™ Herpes microarray assay has achieved excellent results in an international multicenter clinical evaluation study. The Prove-it™ Herpes diagnostic assay simultaneously identifies eight clinically significant herpesviruses in only two hours, enabling quick choice of correct treatment. The performance and safety of the PCR- and microarray-based Prove-it™ Herpes assay were validated with 460 cerebrospinal fluid (CSF) samples at six European clinical laboratories. In the study, the assay was compared to the current PCR-based methods. Prove-it™ Herpes showed clinical sensitivity of 92 % and specificity of 98 %. In 20 of the 460 examined samples, the test uncovered pathogens not found by the reference methods. Furthermore, the test demonstrated 12 multi-infections which were missed by current diagnostics and identified 15 patients with an HHV7 infection not found by the reference methods.

Read the whole Press Release here.